西酞普兰合并丁螺环酮治疗难治性抑郁症33例

A Clinical Control Study of Combined Buspirone and Citalopram in Treatment of Refractory Depression

目的观察西酞普兰合并丁螺环酮治疗难治性抑郁症的疗效和安全性。方法将67例患者随机分为合用组(33例)和单用组(34例),分别给予西酞普兰(34.7±5.2)mg/d+丁螺环酮(35.7±5.6)mg/d、单用西酞普兰(35.1±4.9)mg治疗,疗程均为8周,采用汉密顿抑郁量表(HAMD)、临床疗效总评量表(CGI)、副反应量表(TESS)评定疗效和不良反应。结果治疗8周后合用组HAMD,CGI评分下降较单用组更明显,起效更快,不良反应相仿且均较轻微。结论西酞普兰合并丁螺环酮是目前治疗难治性抑郁症的一种安全、有效的方法。

Objective To observe the efficacy and side effects of combined buspirone and citalopram in the treatment of refractory depression. Methods 67 patients with refractory depression were randomly assigned to two groups （buspirone and citalopram or citalopram alone） for 8 weeks. Efficacy and side effects were assessed with Hamilton depression rating scale （HAMD）, the clinical global impression scale （CGD and treatment emergent symptom scale （TESS）. Results As compared with the baseline scores, the total HAMD, CGI scores decreased significantly in buspirone- citalopram group than in citalopram group after 8 weeks of treatment, but there was no significant difference in TESS. Conclusion Buspirone- citalopram is one of safe and effective methods to treat refractory depression.